Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy

Mario Airoldi, Antonella De Stefani, Sara Marchionatti, Fulvia Pedani, Pietro Gabriele, Riccardo Ragona, Giorgio Cortesina, Cesare Bumma

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods. Thirty patients with recurrent/persistent head and neck cancer were treated with cisplatin (100 mg/m2) d.1.5-fluorouracil (1 gr/m2/d c.i. 96 h), and SQ rIL-2 (4.5 M IU day 8 to 12 and 15 to 19) every 3 weeks. Results. The overall response rate was 53.3% (95% Cl; 34.4-72.3%): 26.6% complete response (CR) (8 patients) and 26.6% partial response (PR) (8 patients); 6 patients had SD (20%), 8 had PD (26.6%). The median follow-up was 36 months (range, 28-44). The median CR duration is 16.2 months (8.5-39+); the median survival duration of this group has not been reached. The median PR duration was 7.2 months (3-10); the median survival was 13.3 months (10-26). The median overall survival was 14 months. Conclusions. The most impressive finding is the very long survival of CRs patients. This outcome has been reported in other cancer patients with a CR after IL-2 therapy.

Original languageEnglish
Pages (from-to)298-304
Number of pages7
JournalHead and Neck
Volume23
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Drug Therapy
Survival
Head and Neck Neoplasms
Fluorouracil
Cisplatin
Neoplasms
Interleukin-2
Carcinoma, squamous cell of head and neck
T-Lymphocytes
Therapeutics

Keywords

  • Chemotherapy
  • Cisplatin
  • Head and neck cancer
  • IL-2
  • Immunotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Airoldi, M., De Stefani, A., Marchionatti, S., Pedani, F., Gabriele, P., Ragona, R., ... Bumma, C. (2001). Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. Head and Neck, 23(4), 298-304. https://doi.org/10.1002/hed.1034

Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. / Airoldi, Mario; De Stefani, Antonella; Marchionatti, Sara; Pedani, Fulvia; Gabriele, Pietro; Ragona, Riccardo; Cortesina, Giorgio; Bumma, Cesare.

In: Head and Neck, Vol. 23, No. 4, 2001, p. 298-304.

Research output: Contribution to journalArticle

Airoldi, M, De Stefani, A, Marchionatti, S, Pedani, F, Gabriele, P, Ragona, R, Cortesina, G & Bumma, C 2001, 'Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy', Head and Neck, vol. 23, no. 4, pp. 298-304. https://doi.org/10.1002/hed.1034
Airoldi, Mario ; De Stefani, Antonella ; Marchionatti, Sara ; Pedani, Fulvia ; Gabriele, Pietro ; Ragona, Riccardo ; Cortesina, Giorgio ; Bumma, Cesare. / Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. In: Head and Neck. 2001 ; Vol. 23, No. 4. pp. 298-304.
@article{554093466c2d43c8903762b399c083de,
title = "Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy",
abstract = "Background. We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods. Thirty patients with recurrent/persistent head and neck cancer were treated with cisplatin (100 mg/m2) d.1.5-fluorouracil (1 gr/m2/d c.i. 96 h), and SQ rIL-2 (4.5 M IU day 8 to 12 and 15 to 19) every 3 weeks. Results. The overall response rate was 53.3{\%} (95{\%} Cl; 34.4-72.3{\%}): 26.6{\%} complete response (CR) (8 patients) and 26.6{\%} partial response (PR) (8 patients); 6 patients had SD (20{\%}), 8 had PD (26.6{\%}). The median follow-up was 36 months (range, 28-44). The median CR duration is 16.2 months (8.5-39+); the median survival duration of this group has not been reached. The median PR duration was 7.2 months (3-10); the median survival was 13.3 months (10-26). The median overall survival was 14 months. Conclusions. The most impressive finding is the very long survival of CRs patients. This outcome has been reported in other cancer patients with a CR after IL-2 therapy.",
keywords = "Chemotherapy, Cisplatin, Head and neck cancer, IL-2, Immunotherapy",
author = "Mario Airoldi and {De Stefani}, Antonella and Sara Marchionatti and Fulvia Pedani and Pietro Gabriele and Riccardo Ragona and Giorgio Cortesina and Cesare Bumma",
year = "2001",
doi = "10.1002/hed.1034",
language = "English",
volume = "23",
pages = "298--304",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy

AU - Airoldi, Mario

AU - De Stefani, Antonella

AU - Marchionatti, Sara

AU - Pedani, Fulvia

AU - Gabriele, Pietro

AU - Ragona, Riccardo

AU - Cortesina, Giorgio

AU - Bumma, Cesare

PY - 2001

Y1 - 2001

N2 - Background. We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods. Thirty patients with recurrent/persistent head and neck cancer were treated with cisplatin (100 mg/m2) d.1.5-fluorouracil (1 gr/m2/d c.i. 96 h), and SQ rIL-2 (4.5 M IU day 8 to 12 and 15 to 19) every 3 weeks. Results. The overall response rate was 53.3% (95% Cl; 34.4-72.3%): 26.6% complete response (CR) (8 patients) and 26.6% partial response (PR) (8 patients); 6 patients had SD (20%), 8 had PD (26.6%). The median follow-up was 36 months (range, 28-44). The median CR duration is 16.2 months (8.5-39+); the median survival duration of this group has not been reached. The median PR duration was 7.2 months (3-10); the median survival was 13.3 months (10-26). The median overall survival was 14 months. Conclusions. The most impressive finding is the very long survival of CRs patients. This outcome has been reported in other cancer patients with a CR after IL-2 therapy.

AB - Background. We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods. Thirty patients with recurrent/persistent head and neck cancer were treated with cisplatin (100 mg/m2) d.1.5-fluorouracil (1 gr/m2/d c.i. 96 h), and SQ rIL-2 (4.5 M IU day 8 to 12 and 15 to 19) every 3 weeks. Results. The overall response rate was 53.3% (95% Cl; 34.4-72.3%): 26.6% complete response (CR) (8 patients) and 26.6% partial response (PR) (8 patients); 6 patients had SD (20%), 8 had PD (26.6%). The median follow-up was 36 months (range, 28-44). The median CR duration is 16.2 months (8.5-39+); the median survival duration of this group has not been reached. The median PR duration was 7.2 months (3-10); the median survival was 13.3 months (10-26). The median overall survival was 14 months. Conclusions. The most impressive finding is the very long survival of CRs patients. This outcome has been reported in other cancer patients with a CR after IL-2 therapy.

KW - Chemotherapy

KW - Cisplatin

KW - Head and neck cancer

KW - IL-2

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0035088068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035088068&partnerID=8YFLogxK

U2 - 10.1002/hed.1034

DO - 10.1002/hed.1034

M3 - Article

VL - 23

SP - 298

EP - 304

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 4

ER -